.jpg?format=webp&quality=80&width=3840)
This study compared the risk of ventricular arrhythmias and sudden death in NYHA class I and NYHA class II-III patients with non-ischaemic cardiomyopathy. The primary endpoint occurred in 8% of the 698 patients during the median follow-up of 31 months, with no differences between NYHA class I and NYHA class II-III cases. Late gadolinium enhancement was the only independent predictor of the primary outcome in both groups. NYHA class I patients with high-risk factors, such as LGE, have a high risk and could benefit from primary prevention ICD at least as much as those in NYHA class II-III with the same risk factors. The risk of the secondary endpoint was significantly higher in patients in NYHA class II-III as compared to those in NYHA class I.
Like
Save
Share